|
|
 |
 |
| Drug Discovery is administered by Osney Media. |
|
|
|
|
 Speakers |
|
|
|
Our carefully researched speaker programmes are further enhanced by the opportunity for the delegates and speakers to discuss topics of interest in more detail during panel and round table discussions. This means that the attendees not only benefit from the expertise of the high level speaker panel but also that of the other delegates.
If you have a cutting edge case study or a presentation and would like to join the speaker panel at one of our events, please contact Mike Burden at m.burden@oxfordglobal.co.uk
2009 Advisory Panel Includes:
Gerhard Mueller, Managing Director and CSO, Proteros fragments GmbH
Bahija Jallal, Vice President, Translational Sciences, MedImmune
Samantha O’Connor, Director, Worldwide Business Development, Pfizer
Martin Klumpp, Lab Head Assay Development and Screening, Novartis
Emilo Diez, Site Director, Molecular Discovery Research, GlaxoSmithKline
Anthony Davies, HCA Research Facility Manager, Trinity College Dublin
Tim Hammonds, Head of Biochemistry and HTS, Cancer Research Technology
Taoufik Ouatas, Senior Scientist, Exploratory Development Department, Astellas Pharma Europe B.V
Zoran Rankovic, Associate Director, Medicinal Chemistry, Organon UK, Schering-Plough
2009 speakers:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aldermar Degroot, Translational Scientist, Translational Medicine Group Leader, Astellas
|
|
|
|
Nicolas Frey, Global Head of Modelling and Simulation, F. Hoffman-La Roche
|
|
|
|
Philip Hajduk, Senior Project Leader, Structural Biology and Lead Discovery, Abbott Laboratories
|
|
|
|
John Haurum, Chief Scientific Officer, Symphogen A/S
|
|
|
|
Jonathon Knowles, President of Group Research F. Hoffman-La Roche
|
|
|
|
Ismail Kola, Senior Vice President, Discovery Research, Early Clinical Research and Experimental Medicine, Schering Plough
|
|
|
|
Phil L'Huillier, Director, Business Management, Cancer Research Technology Limited
|
|
|
|
Jonathon Mason, Divisional Director, Early Lead Generation and Computational Chemistry, Lundbeck Research
|
|
|
|
Lorenz Mayr, Executive Director, BioChemical Assay Development & Screening, Novartis
|
|
|
|
Andy Merritt, Director Discovery Medicinal Chemistry, GlaxoSmithKline
|
|
|
|
Shintaro Nishimura, Senior Director, Bioimaging, Astellas Japan
|
|
|
|
Philip Oliver, Associate Director for Global External R&D Europe, Eli Lilly
|
|
|
|
Paul Passier, Senior Scientist Exploratory Medicine, Astellas
|
|
|
|
Graham Richards, Former Head of Chemistry Department, Oxford University
|
|
|
|
Hans Guenter Schaefer, Director, Clinical Pharmacokinetics/Pharmacodynamics, Boehringer Ingeleheim
|
|
|
|
Bernd Seihelmer, Head Global R&D Risk Management, Bayer Schering
|
|
|
|
Thomas Senderovitz, Vice President Global Exploratory Development, UCB Pharma SA
|
|
|
|
Ted Torphy, CSO and Head, External Research & Early Development, Johnson & Johnson
|
|
|
|
Lex Van der Ploeg, Vice President Basic Research, Site Head Research Laboratories Boston, Merck
|
|
|
|
Chris van Koppen, Director, Molecular Pharmacology, Schering-Plough Corporation
|
|
|
|
Malcolm Weir, CEO, Heptares Therapeutics
|
|
|
|
Alan Wilson, Vice President Drug Metabolism, Pharmacokinetics and Toxicology, Lexicon Pharmaceuticals
|
|
|
|
Ming-Qiang Zhang, Vice President Research, Biotica Technology Ltd
|
|
|
|
|
|
|
|
|
|
|
